Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
Ematobase.it
Dermabase.it

Patients with systemic lupus erythematosus ( SLE ) are at risk of irreversible damage across multiple organ systems because of both active disease and medication toxicities. The severity and freque ...


Pain is one of the most important domains affecting health-related quality of life ( HRQoL ) in patients with psoriatic arthritis ( PsA ). Secukinumab ( Cosentyx ) has demonstrated rapid and sustain ...


Findings from two phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis ( AS ), also referred to as radiographic axial spondyloarthritis ( axSpA ), were presented at the American ...


In 2016, the National Institute for Health and Care Excellence ( NICE ) approved the use of Belimumab ( Benlysta ) for the treatment of autoantibody-positive systemic lupus erythematosus ( SLE ). I ...


FKB327 ( Hulio ) is a proposed biosimilar of the Adalimumab Reference Product ( RP; Humira ). A randomized, double-blind, phase 3 study compared the efficacy, safety, pharmacokinetics and immunogeni ...


Psoriatic arthritis ( PsA ) is an inflammatory arthropathy, associated with skin and/or nail psoriasis. Real world data on efficacy and safety of TNF-alpha blockers in the elderly with psoriatic art ...


A study has evaluated the effectiveness of oral Glucosamine in subgroups of people with hip or knee osteoarthritis ( OA ) based on baseline pain severity, body mass index ( BMI ), sex, structural abno ...


Results from the phase 3 SELECT-MONOTHERAPY clinical trial were announced. This ongoing study evaluated Upadacitinib ( ABT-494 ), an investigational oral JAK1-selective inhibitor, as a monotherapy t ...


Results from the phase 3 SELECT-BEYOND clinical trial evaluating Upadacitinib ( ABT-494 ), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis wh ...


Results of the landmark PRECISION ( Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen Or Naproxen ) trial demonstrated similar rates of cardiovascular risk in patients trea ...


New data showing Secukinumab ( Cosentyx ) delivers sustained improvements in the signs and symptoms of psoriatic arthritis over three years, including patient-reported pain, were presented at the 2016 ...


In a phase III, double-blind 24-week study, RA-BUILD, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to grea ...


Anifrolumab is an investigational, fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, inhibiting the activity of all type I IFNs, which play a central role in lupus, i ...


The results from the phase III study known as GiACTA, which evaluated Tocilizumab ( Actemra, RoActemra ), an anti-IL-6 receptor monoclonal antibody, in people with giant cell arteritis ( GCA ) were pr ...


Cardiovascular disease ( CVD ) is the leading cause of death in rheumatoid arthritis ( RA ) patients. This study is the first to report the association of Hydroxychloroquine ( Plaquenil; an antirheuma ...